Melflufen for Elderly Patients With Relapsed Myeloma
This is a pilot study aimed to evaluate the efficacy and tolerability of melflufen plus dexamethasone in elderly patients at second relapse.

Thirty elderly patients at second or subsequent relapse.
Relapse Multiple Myeloma
DRUG: Melflufen|DRUG: Dexamethasone
Overall Response Rate, rate of participants who achieve a PR or better (PR+VGPR+CR+sCR) according to IMWG response criteria during the treatment., approximately 6 months after the enrolled of the last participant and an updated analysis will be conducted at approximately 8 to 12 months.
DURATION OF RESPONSE, the time from the date of first documented response (≥PR) to the date of first confirmed PD., after 2.5 years|PROGRESSION-FREE SURVIVAL, the time from the date of 1st dose of study drug to the date of first confirmed PD or death due to any cause, whichever occurs first., after 6 months|TIME TO PROGRESSION, the time from the date of 1st dose of study drug to the date of first documented PD, after 2.5 years|PROGRESSION-FREE SURVIVAL 2, the time from the date of 1st dose of study drug to the date of event, which is defined as death from any cause or PD that starts after the next line of therapy, whichever occurs first., after 2.5 years|OVERALL SURVIVAL, the time from the date of 1st dose of study drug to the date of death., after 2.5 years|TIME TO RESPONSE, the time from the date of 1st dose of study drug to the first documented response (≥PR)., after 2.5 years
This is a pilot study aimed to evaluate the efficacy and tolerability of melflufen plus dexamethasone in elderly patients at second relapse.

Thirty elderly patients at second or subsequent relapse.